Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Cephalon France
Woman Max 99 years
Cephalon France
Update Il y a 4 ans
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast Cancer
To compare the efficacy of up to 8 cycles (24 weeks) of MYOCET plus cyclophosphamide and trastuzumab for 4 cycles followed by docetaxel plus trastuzumab for 4 cycles (MCH→TH) with free doxorubicin plu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Cephalon France
Update Il y a 4 ans
A European Multicenter Open-label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
The primary objective of the study is to compare the percentage of patients reaching an effective fentanyl buccal tablet (FBT) dose with a starting dose of 100 mcg (Group A) to those with a starting d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Cephalon France
Update Il y a 4 ans
The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used with mood stabilizers in subjects with major depression associated with bipolar I disorder. Lo scopo di questo studio e' valutare la sicurezza, efficacia e la tollerabilita' di armodafinil quando e' utilizzato come stabilizzatore dell'umore in soggetti con Depressione maggiore associata a disturbo Bipolare di Tipo I
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for trea...
Country
None
organs
None
Specialty
None
Closed trial
More information